HUMANIZED ANTl-HMGB1 ANTIBODY OR ANTIGEN-BINDING FRAGMENT THEREOF
AssigneesEvec Inc., National University Corporation Okayama Universtity
InventorsKenzo TAKADA, Takashi TORASHIMA, Masahiro NISHIBORl
Life of this patent
Estimating the term…
Abstract
The present invention provides a humanized anti-HMGB1 antibody which specifically binds to a sequence consisting of the C-terminal 8 amino acid residues (EEEDDDDE) of HMGB1 protein and is effective for treatment or prevention of various inflammatory diseases related to this protein, as well as an antigen-binding fragment thereof. The present invention also provides a pharmaceutical composition comprising such an antibody or antigen-binding fragment thereof.
Claims16
A humanized antibody specifically binding to an amino acid sequence (EEEDDDDE (SEQ ID NO:
- 60)) present in the C-terminal domain of HMGB1 protein, or an antigen-binding fragment thereof, comprising a heavy chain variable region (VH) and a light chain variable region (VL), wherein
- (i) the heavy chain variable region (VH) comprises:
- (a) an amino acid sequence of heavy chain CDR1 comprising the amino acid sequence of SEQ ID NO:
- 7 or an amino acid sequence having mutations of deletion, substitution, insertion and/or addition of one to several amino acid residues in the amino acid sequence of SEQ ID NO:
- 7,
- (b) an amino acid sequence of heavy chain CDR2 comprising the amino acid sequence of SEQ ID NO:
- 8 or an amino acid sequence having mutations of deletion, substitution, insertion and/or addition of one to several amino acid residues in the amino acid sequence of SEQ ID NO:
- 8;
- and
- (c) an amino acid sequence of heavy chain CDR3 comprising the amino acid sequence of SEQ ID NO:
- 9 or an amino acid sequence having mutations of deletion, substitution, insertion and/or addition of one to several amino acid residues in the amino acid sequence of SEQ ID NO:
- 9, and
- (ii) the light chain variable region (VL) comprises:
- (a) an amino acid sequence of light chain CDR1 comprising the amino acid sequence of SEQ ID NO:
- 10 or an amino acid sequence having mutations of deletion, substitution, insertion and/or addition of one to several amino acid residues in the amino acid sequence of SEQ ID NO:
- 10,
- (b) an amino acid sequence of light chain CDR2 comprising the amino acid sequence of SEQ ID NO:
- 11 or an amino acid sequence having mutations of deletion, substitution, insertion and/or addition of one to several amino acid residues in the amino acid sequence of SEQ ID NO:
- 11;
- and
- (c) an amino acid sequence of light chain CDR3 comprising the amino acid sequence of SEQ ID NO:
- 12 or an amino acid sequence having mutations of deletion, substitution, insertion and/or addition of one to several amino acid residues in the amino acid sequence of SEQ ID NO:
- 12.
Dependencies are inferred from the claim text.